Juvenile Idiopathic Arthritis (JIA)
Conditions
Keywords
Balance, gait, muscle strength, physical function
Brief summary
The purpose of this study is to evaluate the short-term clinical effects of intra-articular corticosteroid injections on knee joint functions in children and adolescents diagnosed with Juvenile Idiopathic Arthritis (JIA). Patients who receive a corticosteroid injection into the knee joint as part of their routine medical treatment will be monitored prospectively. The study aims to assess changes in range of motion, functional status, and pain levels before the injection and during the early follow-up period after the procedure. This will help healthcare providers better understand the immediate benefits and functional outcomes of this treatment in youth sports and daily physical activities.
Interventions
Patients diagnosed with juvenile idiopathic arthritis (JIA) underwent a routine clinical knee intra-articular corticosteroid injection (IACI) due to active knee involvement. Clinical, functional, and physical strength assessments were performed prospectively at three specific time points: before the injection (baseline, T0), at 2 weeks post-treatment (T1), and at 2 months post-treatment (T2) to evaluate short-term outcomes.
Sponsors
Necmettin Erbakan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
8 Years to 16 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with juvenile idiopathic arthritis (JIA) according to standard criteria (arthritis with onset before the age of 16 years and duration longer than 6 weeks with no other identifiable cause). * Having unilateral or bilateral active knee joint arthritis. * Undergoing knee intra-articular corticosteroid injection (IACI) for the active knee joint involvement. * Provision of written informed consent by both patients and their caregivers.
Exclusion criteria
* Presence of other chronic rheumatological diseases. * Initiation or discontinuation of systemic steroids, conventional disease-modifying anti-rheumatic drugs (DMARDs) (e.g., methotrexate, sulfasalazine), or biologic DMARDs (e.g., inhibitors of TNF, IL-1, or IL-6) within the 3 months before knee IACI and during the follow-up period. * History of severe adverse reactions to steroids. * Presence of neurological diseases. * History of lower extremity surgery. * Missing data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Pain Intensity | Baseline (T0), 2 weeks (T1), and 2 months (T2) post-injection | Pain intensity assessed at rest and during physical activity using a standard assessment scale. |
Countries
Turkey (Türkiye)
Outcome results
None listed